Renal / Liver Diseases
Proceedings of the Guideline Workshop 2019 –Strategies for the optimization of guideline
processes in diabetes, cardiovascular diseases and
Nikolaus Marx, Lars Ryde´n , Frank Brosius , Antonio Ceriello , Michael Cheung , Francesco Cosentino , Jennifer Green , Monika Kellerer , Susan Koob ,
Mikhail Kosiborod , Prashant Nedungadi , Helena W. Rodbard , Per Olav Vandvikm, Eberhard Standl , Oliver Schnell n
The Guideline Workshop 2019, held in October 2019 in Munich, Germany, had the purpose of facilitating discussion on strategies for optimization of guideline processes in diabetes amongst a group of representatives of renown national and international societies in the field of diabetes, cardiology, and nephrology.
Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication
Zachary Bloomgarden, Yehuda Handelsman
A somewhat underappreciated cause of optimism has been the evidence from the cardiovascular outcome trials
of type 2 diabetes (T2D) treatments that all the newer agents appear to improve aspects of renal function.
The 2.6-year CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial randomizing 4401 persons with T2D, estimated
glomerular filtration rate (eGFR) 30-90 mL/min/1.73m2 (mean baseline 56), and angiotensin-converting-enzyme
inhibitor (ACEI) or angiotensin-receptor blocker (ARB)- treated macroalbuminuria (>300 mg/g creatinine) to canagliflozin
100 mg daily or placebo showed highly significant reduction in renal disease outcomes